Treatment duration in acute hepatitis C: The issue is not solved yet [1]

Hepatology

Volumn 44, Issue 4, 2006, Pages 1051-

  Wedemeyer, Heiner ^a   Cornberg, Markus ^a   Wiegand, Johannes ^a   Manns, Michael ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON;

ACUTE HEPATITIS; CLINICAL TRIAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS GENOME; VIRUS LOAD; DRUG ADMINISTRATION; EGYPT; METHODOLOGY; NOTE; PATIENT SELECTION; STANDARD; STATISTICAL ANALYSIS;

CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; DRUG ADMINISTRATION SCHEDULE; EGYPT; HEPATITIS C; HUMANS; PATIENT SELECTION;

EID: 33750604929     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21348     Document Type: Letter

References (6)

1. Kamal SM, Moustafa KN, Chen J, Fehr J, Moneim AA, Khalifa KE, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. HEPATOLOGY 2006;43:923-931.
2. Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006;130:632-638.
3. Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. HEPATOLOGY 2004;39:1721-1731.
4. Kamal SM, Madwar MA, He Q, Al Fouly A, Ismail A, El Sayed K, et al. Peginterferon alfa compared with conventional interferon alfa and ribavirin combination therapy in asymptomatic acute hepatitis C: A randomized trial of treatment onset, duration and cost-effectiveness [Abstract]. HEPATOLOGY 2004;40(Suppl):178A.
5. Kamal S, Ismail A, Al Tawil A, Hakam S, He Q, Rasenack J, et al. Peginterferon alfa 2-B therapy for 8 weeks in acute hepatitis C genotypes 1 and 4: a pilot study [Abstract]. Gastroenterology 2005;128:A683.
6. Kamal S, He Q, Al Tawil A, Khalifa K, Hakam S, Saleh W, et al. Peginterferon alpha-2b therapy in acute hepatitis C: impact of onset and duration of therapy on sustained virologic response [Abstract]. J Hepatol 2005;42:8.